Hani Ashamalla, MD
Radiation Oncology · Brooklyn, NYNPI 1467435701
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,750 of the $6,814 with a category attached, or 84.4%. Bayer accounts for 84.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $5,769 and has fallen 97.3% since, to $153 in 2025.
Across 28 payments — averaging $243.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$6K
- Sirtex Medical Inc$356
- Siemens Medical Solutions USA, Inc.$255
- Novocure Inc.$144
- Boston Scientific$95
- GT Medical Technologies, Inc$62
- plus $117 from 4 others
What the payments were for
- Consulting fees$5,75084%
- Food & beverage$1,06416%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 3 | $5,784 |
| Sirtex Medical Inc | 5 | $356 |
| Siemens Medical Solutions USA, Inc. | 2 | $255 |
| Novocure Inc. | 7 | $144 |
| Boston Scientific | 3 | $95 |
| GT Medical Technologies, Inc | 2 | $62 |
| Telix Pharmaceuticals | 2 | $43 |
| Novartis | 1 | $28 |
| Myovant Sciences Inc. | 1 | $25 |
| Isoray, Inc | 2 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xofigo$5,750
- SIR-Spheres Microspheres$297
- Varian Ethos Treatment Planning$146
- TrueBeam$109
How this compares
$6,814 in reported general payments places this provider in the 85th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 18 | $205 |
| SsdSilver Sulfadiazine | 15 | $139 |
| Fluconazole | 15 | $112 |
| Silver Sulfadiazine | 19 | $98 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Brooklyn
- David BerlachBrooklyn$6K
- Thomas DanielsBrooklyn$4K
- Chung ChungSyracuse$3.1M
- Michael ZelefskyNew York$946K
- Jeffrey BogartSyracuse$772K
- Steven FinkelsteinSyracuse$578K
- Shawn ZimbergPlainview$411K
- Edward ObedianOyster Bay$391K
- Nancy LeeNew York$233K
- Dheerendra PrasadBuffalo$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.